(Q66397413)

English

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

title

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Advanced Pancreatic Cancer That Has Progressed Through One or More Lines of Therapy (English)

0 references

medical condition

adenocarcinoma

0 references

country

United States of America

0 references

start time

20 December 2016

0 references

end time

25 October 2017

0 references

number of participants

13

0 references

research intervention

tetrahydrouridine

0 references

clinical trial phase

phase I clinical trial

0 references

minimum age

18 year

0 references

study type

interventional study

0 references

Identifiers

ClinicalTrials.gov ID

NCT02847000

0 references

(Q66397413)

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)